Tyra Biosciences VP reports stock option holdings
Tyra Biosciences, Inc. filed an initial insider report for Yuliya Rueb, Vice President, Finance (PAO), outlining her existing stock option holdings.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
3
Rhea-AI Filing Summary
Tyra Biosciences, Inc. filed an initial insider report for Yuliya Rueb, Vice President, Finance (PAO), outlining her existing stock option holdings. The filing lists several options to buy common stock with exercise prices ranging from $6.50 to $21.57 per share and expirations between 2032 and 2035.
Each grant vests over time. One option began vesting on October 18, 2023 with 25% vested then and the remainder vesting monthly. Other grants vest in 48 monthly installments following commencement dates in July 2024, August 2024, and August 2025, conditioned on her continued service.
Insider Trade Summary
Holdings reported, no transactions
Holdings
Insider
Rueb Yuliya
Role
Vice President, Finance (PAO)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
| Holding | Stock Option (Right to Buy) | -- | -- | -- |
Holdings:
Stock Option (Right to Buy) — 84,726 contracts (Direct)
Footnotes (4)
- F1. 25% of the shares subject to the option vested on October 18, 2023, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- F2. 25% of the shares subject to the option vested on July 28, 2024, and 1/48th of the total number of shares subject to the option vest monthly thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- F3. 1/48th of the shares subject to the option vest monthly following August 14, 2024, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
- F4. 1/48th of the shares subject to the option vest monthly following August 7, 2025, the vesting commencement date, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
Key Figures
Option exercise price: $6.50/share
Underlying shares: 9,034 shares
Option exercise price: $10.75/share
+5 more
8 metrics
Option exercise price
$6.50/share
Stock Option (Right to Buy), expiration November 3, 2032
Underlying shares
9,034 shares
Option at $6.50, underlying common stock
Option exercise price
$10.75/share
Stock options expiring July 27, 2033 and August 6, 2035
Underlying shares
34,875 shares
Options at $10.75 with 3,484 and 35,021 underlying shares
Option exercise price
$14.35/share
Stock Option (Right to Buy), expiration July 27, 2033
Underlying shares
10,312 shares
Option at $14.35 for common stock
Option exercise price
$21.57/share
Stock Option (Right to Buy), expiration August 13, 2034
Underlying shares
26,875 shares
Option at $21.57 for common stock
Key Terms
Stock Option (Right to Buy), exercise price, underlying common stock, vesting commencement date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 6.5000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying common stock financial
"underlying_security_title: Common Stock"
vesting commencement date financial
"the vesting commencement date, subject to the Reporting Person's continuous service"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer through each vesting date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the TYRA Form 3 filing for Yuliya Rueb show?
The Form 3 shows Vice President, Finance (PAO) Yuliya Rueb reporting her existing stock option holdings in Tyra Biosciences common stock, including exercise prices, expiration dates, and time-based vesting schedules tied to her continued service with the company.
How many stock option grants does Yuliya Rueb report at Tyra Biosciences (TYRA)?
The filing lists five stock option grants for Yuliya Rueb. Each grant has a specific exercise price, expiration date, and number of underlying common shares, with vesting occurring either partly upfront or in 48 monthly installments after the vesting commencement date.
What are the exercise prices of Yuliya Rueb’s TYRA stock options?
Her reported stock options carry exercise prices of $6.50, $10.75, $14.35, and $21.57 per share. Each price applies to a specific grant and defines the cost per share she would pay to purchase Tyra Biosciences common stock under that option.
When do Yuliya Rueb’s Tyra Biosciences stock options expire?
The options reported in the Form 3 expire between November 3, 2032 and August 6, 2035. Each grant includes a fixed expiration date, after which any unexercised portion of that particular option can no longer be used to acquire Tyra Biosciences common shares.
How do the TYRA stock options reported by Yuliya Rueb vest over time?
One option vested 25% on October 18, 2023, with the rest vesting monthly. Other grants vest as 1/48th monthly after commencement dates in July 2024, August 2024, and August 2025, all subject to her continuous service with Tyra Biosciences.
Does the TYRA Form 3 indicate any stock purchases or sales by Yuliya Rueb?
No purchases or sales are indicated. The Form 3 functions as an initial ownership report, listing Rueb’s existing stock option positions and their vesting and expiration terms, rather than reporting new open-market transactions in Tyra Biosciences common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
